Battelle said today that it’s partnering with the Feinstein Institute to develop a novel “neural tourniquet” designed to staunch blood loss using neurostimulation. The device functions by electrically stimulating neural pathways to the spleen, which prepares platelets in the blood for clotting in the event of a wound, Battelle said. Applications anticipated for the device include pre-operative […]
Big data – from electronic health records, bio-feedback from wearables and remote monitoring systems that communicate with medical implants – is changing how medical devices are created and designed. MassDevice.com spoke to a pair of researchers at Battelle – David Giles, senior director of medical devices and health analytics and Stephanie Kute, platform lead for the […]
Researchers touted a major breakthrough this week when a paraplegic patients successfully moved his own hand using only signals from his own mind.
The technology is comprised of a microchip implanted in the brain and a "sleeve" laden with electrodes that stimulates the muscles in the arm in precise coordination with signals from the brain. Unlike other technologies that rely on robotics or computers to move paralyzed limbs, the so-called "NeuroBridge" system translates brain signals into muscle stimulation.
Although the FDA has only recently begun addressing medical device cybersecurity in an official capacity, device makers would do well to take notice that the agency has ramped up its oversight quickly over the last year.
Medical device executives and Ted Talk-ers love comparing the medtech industry to consumer electronics or aeronautics when making grand points about the market, but at Battelle cross-industry correlations speak to the core of the company’s engineering philosophy.
MASSDEVICE ON CALL — The Mass. Life Sciences Center, a quasi-public agency that oversees state dollars allocated toward increasing the life sciences industry’s footprint in the Bay State, doled out another $3.8 million in “accelerator” loans.
The program is designed to provide a boost to early-stage life science companies that the center’s scientific advisory board deems to have a high potential for commercialization, rapid growth and the ability to raise substantial capital.